Brief: Aravive Reports Third Quarter 2020 Financial Results And Provides Corporate Updates

Aravive

05/11/2020 23:15

Nov 5 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND
PROVIDES CORPORATE UPDATES
    * EXPECTS TO INITIATE PIVOTAL TRIAL OF AVB-500 IN PLATINUM
RESISTANT OVARIAN CANCER DURING Q4 2020/Q1 2021, BASED ON PHASE
1B RESULTS
    * ON-TRACK TO INITIATE PHASE 1B/2 TRIAL OF AVB-500 IN CLEAR
CELL
RENAL CELL CARCINOMA DURING Q4 2020
    * CURRENT CASH AND CASH EQUIVALENTS EXPECTED TO FUND
OPERATIONS
INTO 2022
    * QTRLY LOSS PER SHARE $0.66
    * Q3 EARNINGS PER SHARE VIEW $-0.42 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXb0Gqjr 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))